A Comparative Cost Utility Analysis For First Line Treatment Of Metastatic Non-Small Cell Lung Cancer (Nsclc) Patients With Egfr Exon 19 Deletions Or Exon 21 (L858r) Substitution Mutations
May 1, 2015, 00:00
10.1016/j.jval.2015.03.033
https://www.valueinhealthjournal.com/article/S1098-3015(15)00090-X/fulltext
Title :
A Comparative Cost Utility Analysis For First Line Treatment Of Metastatic Non-Small Cell Lung Cancer (Nsclc) Patients With Egfr Exon 19 Deletions Or Exon 21 (L858r) Substitution Mutations
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)00090-X&doi=10.1016/j.jval.2015.03.033
First page :
A5
Section Title :
Cancer Outcomes Research Studies
Open access? :
No
Section Order :
1386